# Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

> **NCT03267940** · PHASE1 · TERMINATED · sponsor: **Halozyme Therapeutics** · enrollment: 85 (actual)

## Conditions studied

- Cholangiocarcinoma Non-resectable
- Cholangiocarcinoma, Intrahepatic
- Cholangiocarcinoma, Extrahepatic
- Gallbladder Adenocarcinoma

## Interventions

- **DRUG:** PEGPH20
- **DRUG:** CIS
- **DRUG:** GEM
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03267940
- **Lead sponsor:** Halozyme Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-02
- **Primary completion:** 2019-11-11
- **Final completion:** 2019-11-11
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2020-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03267940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03267940, "Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03267940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*